This content is from: Premium
OrbiMed gains on Amarin’s hearty rally
Amarin's latest clinical test results suggest that the drug is on track to win Food and Drug Administration approval this year.
By Pete Gallo Sam Isaly’s biotech and pharma hedge fund looks to have a winner on its hands. OrbiMed Healthcare Fund Management is the largest shareholder in Amarin, a biopharmaceutical firm whose stock has produced spectacular results, thanks to a recent flurry of positive clinical trials for a cardiovascular drug
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.